A New Dawn in HCM: Rise of the RCTs
- PMID: 34915983
- DOI: 10.1016/j.jacc.2021.10.025
A New Dawn in HCM: Rise of the RCTs
Keywords: beta-blocker; diastolic function; exercise capacity metoprolol; left ventricular outflow tract obstruction; obstructive hypertrophic cardiomyopathy.
Conflict of interest statement
Funding Support and Author Disclosures Dr Masri has received research grants from Pfizer, Ionis, Akcea, and Ultromics; and has received fees from Eidos, Pfizer, Ionis, Akcea, Alnylam, Cytokinetics, and Attralus.
Comment on
-
Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy.J Am Coll Cardiol. 2021 Dec 21;78(25):2505-2517. doi: 10.1016/j.jacc.2021.07.065. J Am Coll Cardiol. 2021. PMID: 34915981 Clinical Trial.
-
Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.J Am Coll Cardiol. 2021 Dec 21;78(25):2518-2532. doi: 10.1016/j.jacc.2021.09.1381. J Am Coll Cardiol. 2021. PMID: 34915982 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources